WAY vs COLL

For growth investors, Collegium Pharmaceutical, Inc.

(COLL) is the stronger pick with 23. 6% revenue growth year-over-year, versus 16. 5% for Waystar Holding Corp. (WAY). Collegium Pharmaceutical, Inc. (COLL) offers the better valuation at 20. 0x trailing P/E (4. 5x forward), making it the more compelling value choice. Analysts rate Waystar Holding Corp. (WAY) a "Buy" — based on 17 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Collegium Pharmaceutical, Inc.

(COLL) is the cheapest at 20. 0x versus Waystar Holding Corp. at 30. 7x. On forward P/E, Collegium Pharmaceutical, Inc. is actually cheaper at 4. 5x.

Over the past 5 years, Collegium Pharmaceutical, Inc.

(COLL) delivered a total return of +50. 7%, compared to -9. 4% for Waystar Holding Corp. (WAY). Over 10 years, the gap is even starker: COLL returned +126. 0% versus WAY's -9. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Collegium Pharmaceutical, Inc.

(COLL) is the lower-risk stock at 0. 44β versus Waystar Holding Corp. 's 0. 84β — meaning WAY is approximately 91% more volatile than COLL relative to the S&P 500. On balance sheet safety, Waystar Holding Corp. (WAY) carries a lower debt/equity ratio of 39% versus 3% for Collegium Pharmaceutical, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Collegium Pharmaceutical, Inc.

(COLL) is pulling ahead at 23. 6% versus 16. 5% for Waystar Holding Corp. (WAY). On earnings-per-share growth, the picture is similar: Waystar Holding Corp. grew EPS 569. 2% year-over-year, compared to -7. 0% for Collegium Pharmaceutical, Inc.. Over a 3-year CAGR, COLL leads at 18. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Waystar Holding Corp.

(WAY) is the more profitable company, earning 10. 2% net margin versus 8. 1% for Collegium Pharmaceutical, Inc. — meaning it keeps 10. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: WAY leads at 24. 2% versus 24. 0% for COLL. At the gross margin level — before operating expenses — WAY leads at 64. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Collegium Pharmaceutical, Inc.

(COLL) trades at 4. 5x forward P/E versus 11. 4x for Waystar Holding Corp. — 6. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for WAY: 90. 0% to $35. 62.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Collegium Pharmaceutical, Inc.

(COLL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 44), +126. 0% 10Y return). Both have compounded well over 10 years (COLL: +126. 0%, WAY: -9. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (WAY (Technology) and COLL (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.